[70例淋巴瘤患者的SPECT/PET应用：监测治疗反应]

[Application of SPECT/PET to 70 patients with lymphoma: monitoring response to therapy].

作者信息

Yao Hui, Cen Xi-Nan, Liang Ze-Yin, Ou Jin-Ping, Qiu Zhi-Xiang, Wang Wen-Sheng, Xu Wei-Lin, Li Yuan, Yin Yue, Wang Mang-Ju, Dong Yu-Jun, Wang Li-Hong, Ren Han-Yun

机构信息

Department of Hematology, The First Hospital, Peking University, Beijing 100034, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2010 Oct;31(10):667-70.

PMID:21223716

Abstract

OBJECTIVE

To evaluate the image of SPECT/PET (18)F-FDG in monitoring response to therapy for lymphoma patients.

METHODS

A retrospective study was performed in 83 SPECT/PET studies for 70 patients with lymphoma from 1998 to 2008 in our hospital. The risk factors for survival rate were analyzed by univariate analysis.

RESULTS

Forty patients received SPECT/PET after 2 - 4 cycles of chemotheraphy, the median PFS in patients with positive and negative group were 5.5 months and 15.5 months, 2-year PFS were 12.5% and 66.8%; the median OS were 12.5 months and 17 months, and 1-year OS were 28.8% and 94.1%, respectively, all being of significant difference between two groups (P = 0.003). Forty-three patients performed posttreatment SPECT/PET, the median PFS in patients with positive and negative group were 10 months and 23 months, the 2-year PFS were 23.3% and 83.2%; the median OS were 17 months and 27 months and the 2-year OS were 60.0% and 100% respectively, all being of significant difference (P = 0.001).

CONCLUSION

SPECT/PET has significant value in monitoring response to therapy and predicting prognosis for patients with lymphoma.

摘要

目的

评估SPECT/PET（18）F-FDG在监测淋巴瘤患者治疗反应中的影像表现。

方法

对我院1998年至2008年70例淋巴瘤患者的83次SPECT/PET检查进行回顾性研究。采用单因素分析方法分析生存率的危险因素。

结果

40例患者在化疗2 - 4周期后接受SPECT/PET检查，阳性组和阴性组患者的中位无进展生存期分别为5.5个月和15.5个月，2年无进展生存率分别为12.5%和66.8%；中位总生存期分别为12.5个月和17个月，1年总生存率分别为28.8%和94.1%，两组差异均有统计学意义（P = 0.003）。43例患者进行了治疗后SPECT/PET检查，阳性组和阴性组患者的中位无进展生存期分别为10个月和23个月，2年无进展生存率分别为23.3%和83.2%；中位总生存期分别为17个月和27个月，2年总生存率分别为60.0%和100%，差异均有统计学意义（P = 0.001）。